Established in 2007 as a €2 billion Joint Undertaking (JU) between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI is Europe's largest PPP in health research. It aims to speed up the development of better and safer medicines for patients. IMI funding activities will be concluded by 2014 and the IMI JU by 31 December 2017. On 10 July 2013, the European Commission released its proposal for IMI 2.
For whole article please register, is free.